HYEXHEALTHY EXTRACTS INC.vs its industry peers
A metric-by-metric comparison of HEALTHY EXTRACTS INC. against Medicinal Chemicals & Botanical Products — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HYEX본 종목 | — | — | — | — | 44.9%#1 | 0.7%#4 | -73.7%#5 | -1.5%#1 | — | — | — | — |
| DFTX | $5.3B#1 | — | 5.7x#1 | — | — | -69.1%#9 | — | -20.0%#3 | -55.5%#4 | — | 335.4%#1 | — |
| GLAS | $649M#2 | — | 8.8x#2 | 3.6x#1 | -9.4%#6 | -5814.6%#10 | -9.1%#3 | -40.1%#4 | -13.9%#3 | — | — | — |
| GLUC | — | — | — | — | — | -54.3%#7 | — | — | — | — | — | — |
| IMCC | $18M#4 | — | — | — | — | — | — | — | — | — | -94.8%#3 | — |
| JUSH | — | — | — | — | 2.1%#4 | -40.6%#6 | 1.8%#1 | — | 8.8%#1 | 3#1 | — | — |
| LEEEF | — | — | — | — | 22.1%#2 | 28.4%#1 | -21.8%#4 | — | — | — | — | — |
| MDWD | $171M#3 | — | — | 10.1x#2 | -16.1%#7 | 21.0%#2 | -149.0%#6 | — | — | — | -21.8%#2 | — |
| MRMD | — | — | — | — | 1.3%#5 | -16.2%#5 | -1.8%#2 | -17.5%#2 | -1.7%#2 | 3#1 | — | — |
| NPHC | — | — | — | — | 4.6%#3 | -59.2%#8 | -567.7%#8 | — | — | 2#4 | — | — |
| NTRR | — | — | — | — | -26.1%#8 | 11.3%#3 | -437.8%#7 | — | — | 3#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2833). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-22.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice